Idiopathic pulmonary fibrosis and pirfenidone

被引：15
作者：
Collard, H. R. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2010年 / 35卷 / 04期
关键词：
PLACEBO-CONTROLLED TRIAL; END-POINTS;
D O I：
10.1183/09031936.00006610
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：728 / 729
页数：2
相关论文
共 14 条
  • [1] Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis
    Collard, HR
    King, TE
    Bartelson, BB
    Vourlekis, JS
    Schwarz, MI
    Brown, KK
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) : 538 - 542
  • [2] High-dose acetylcysteine in idiopathic pulmonary fibrosis
    Demedts, M
    Behr, J
    Buhl, R
    Costabel, U
    Dekhuijzen, R
    Jansen, HM
    MacNee, W
    Thomeer, M
    Wallaert, B
    Laurent, F
    Nicholson, AG
    Verbeken, EK
    Verschakelen, J
    Flower, CDR
    Capron, F
    Petruzzelli, S
    De Vuyst, P
    van den Bosch, JMM
    Rodriguez-Becerra, E
    Corvasce, G
    Lankhorst, I
    Sardina, M
    Montanari, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) : 2229 - 2242
  • [3] *INTERMUNE, INV REL
  • [4] BUILD-1:: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
    King, Talmadge E., Jr.
    Behr, Juergen
    Brown, Kevin K.
    du Bois, Roland M.
    Lancaster, Lisa
    de Andrade, Joao A.
    Staehler, Gerd
    Leconte, Isabelle
    Roux, Sebastien
    Raghu, Ganesh
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) : 75 - 81
  • [5] Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial
    King, Talmadge E., Jr.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Hormel, Phil
    Lancaster, Lisa
    Noble, Paul W.
    Sahn, Steven A.
    Szwarcberg, Javier
    Thomeer, Michiel
    Valeyre, Dominique
    du Bois, Roland M.
    [J]. LANCET, 2009, 374 (9685) : 222 - 228
  • [6] Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis
    King, TE
    Safrin, S
    Starko, KM
    Brown, KK
    Noble, PW
    Raghu, G
    Schwartz, DA
    [J]. CHEST, 2005, 127 (01) : 171 - 177
  • [7] Liu Guanghan, 2002, J Biopharm Stat, V12, P207, DOI 10.1081/BIP-120015744
  • [8] Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance
    ONeill, RT
    [J]. CONTROLLED CLINICAL TRIALS, 1997, 18 (06): : 550 - 556
  • [9] A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    Raghu, G
    Brown, KK
    Bradford, WZ
    Starko, K
    Noble, PW
    Schwartz, DA
    King, TE
    Adlakha, A
    Tarczynski, S
    Ainslie, G
    Kalam, R
    Bai, T
    Truchan, H
    Baughman, R
    Wingst, D
    Bhorade, S
    Norwick, L
    Brown, KK
    Kervitsky, D
    Calhoun, W
    DiNella, L
    Chan, C
    Jamieson, L
    Chan, K
    Turpen, T
    Chapman, J
    Slattery, S
    Chen, L
    Turner, J
    Clark, M
    Sanders, R
    Crain, M
    Pate, D
    Davis, G
    Lynn, M
    Dhar, A
    Hrytsytk, M
    Drent, M
    Horr, ET
    du Bois, R
    Goh, N
    Egan, J
    Anthony, N
    Enelow, R
    Haram, T
    Ettinger, N
    Merli, S
    Frost, A
    Holy, R
    Glassberg, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (02) : 125 - 133
  • [10] Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone - Results of a prospective, open-label phase II study
    Raghu, G
    Johnson, WC
    Lockhart, D
    Mageto, Y
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) : 1061 - 1069
12